Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive September 1, 2006	Finance: Good Alternatives With more ways to raise cash, biotechs with hot products can extend their independence.
The Motley Fool December 16, 2011 Brian Orelli	Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value.
Pharmaceutical Executive October 1, 2005 Joseph S. Dillon	Risks and Rewards: How to Protect the Hand You're Dealt Like each bet at the gaming table, the wagers and payoffs of pharma deals must be condsidered on their own merits, using careful due diligence to achieve a beneficial deal structure.
Pharmaceutical Executive June 1, 2011	2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead.
The Motley Fool July 27, 2004 Charly Travers	Cash Concerns at Vertex New royalties might not help offset losses at the pharmaceutical, so it's time to look at the drug pipeline.
Financial Advisor May 2008 Rebecca Pomering	Adding New Owners Internal transition is the desired growth plan and succession plan for the vast majority of advisors and good planning, strategic thinking and thoughtful implementation will allow many to enact a transaction that ensures the desired outcomes for their staff, their clients and themselves.
Commercial Investment Real Estate Jul/Aug 2011 Bill Richert	Creative Currency Unlock your property's potential with equity. In the late 1970s I discovered that incorporating value other than cash is what helps to close transactions.
Commercial Investment Real Estate Nov/Dec 2015 Randall & Misner	Lender Talk Tips Maximize your role in discussions with your financing partner.
Bio-IT World June 17, 2004 Stephanie McRae	Expatriate Your Patents Intellectual property rights, especially patents, are often the principal source of value and revenue for biotechnology companies. You can save a boatload of tax money shipping your IP rights overseas.
Pharmaceutical Executive July 1, 2011 Todd C. Davis	Seeing the Fire Behind the Smoke While crafting license agreements involves all of the tactical tradeoffs expected in a negotiating dynamic, one should try to pay attention to these 10 licensing pitfalls.
Pharmaceutical Executive January 1, 2009 Stan Bernard	Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms.
Chemistry World February 27, 2013 Andrew Turley	Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma.
The Motley Fool August 4, 2004 Charly Travers	Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not.
The Motley Fool April 17, 2008 Brian Lawler	CVT's Copacetic Cash Management Drugmaker CV Therapeutics signs away a little portion of its royalty stream from a recently approved drug, in order to get a lot back.
The Motley Fool April 28, 2011 Brian Orelli	Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable.
The Motley Fool December 13, 2004 Charly Travers	PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success.
Investment Advisor October 2006 Mark Tibergien	The ABCs of IOUs When selling to an insider, financial advisory practice owners have more options than they realize.
Registered Rep. July 24, 2014 David Grau Sr.	Charting Your Succession Course The author delineates the usual alternatives for selling an advisor practice.
Bank Systems & Technology January 1, 2007 Maria Bruno-Britz	Banks Starting to Embrace Concept of Financial Supply Chain Management Financial supply chain management represents a growing opportunity for banks.
Commercial Investment Real Estate Jul/Aug 2008 Essa & Hoskote	Fast Funding Asset-based financing provides quicker access to securing loans.
Bio-IT World Jul/Aug 2006 Michael A. Greeley	Monsoon of Capital The private equity markets, both venture capital and growth equity, while characterized by a number of established firms, continue to struggle with how best to finance early-stage, risky bio-IT companies.
IndustryWeek January 20, 2010 Jill Jusko	A Compelling Proposition At a time when access to capital is hard to come by, Videojet boosts its value proposition as a seller by offering a financing option for its manufactured goods.
HBS Working Knowledge November 13, 2006 Sean Silverthorne	Science Business: What Happened to Biotech? The biotech industry has underperformed expectations, caught in the conflicting objectives and requirements between science and business.
The Motley Fool May 7, 2007 Mike Havrilla	Oscillating Oscient Shares of the tiny drug company have been highly volatile for several reasons.
The Motley Fool July 30, 2007 Brian Orelli	Why Sepracor Investors Can't Sleep Shares of the drug maker were hammered after the company announced lower than expected earnings and a not so bright future.
CFO June 15, 2012 Vincent Ryan	A Better Way to Borrow? Middle-market companies and leveraged-buyout firms are returning to the recent past with a hybrid loan structure that simplifies the use of subordinated debt and offers companies a lower cost of capital.
Commercial Investment Real Estate May/Jun 2009	Financing Links to articles about various aspects of financing for real estate.
Pharmaceutical Executive March 1, 2011	A Rule of Thumb Gets Shot Down The Federal Circuit court continues its trend in tightening the standards for establishing patent damages by leapfrogging a stalled legislative process.
The Motley Fool August 29, 2008 Christopher Barker	The Lean, Mean, Cost-Cutting Machine Miners get creative in efforts to cut costs.
Chemistry World December 4, 2014 Anthony King	Cystic Fibrosis Foundation sells drug royalty rights for $3.3bn The Cystic Fibrosis Foundation has sold royalty rights to treatments developed with support from its 'venture philanthropy' model.
Entrepreneur June 2004 Marc Diener	Fair Share? Whether it's a commission, a participation, a royalty or equity, here are 10 ways to know if you're getting an equal slice of the pie.
The Motley Fool February 13, 2006 Brian Gorman	Albany Molecular's Royalty Squeeze Declining royalty revenue is likely to keep buffeting the contract services provider. Investors, take note.
The Motley Fool July 30, 2007 Brian Orelli	Palomar Plummets In the second quarter, cosmetic-laser maker Palomar Medical Technology had a stellar performance in the former, but investors couldn't look past the lack of royalty payments.
The Motley Fool September 12, 2007 Brian Orelli	Butterflies Move Eastward Sepracor and GlaxoSmithKline ink a deal to market Lunesta worldwide. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia sufferers are on medication, so there's certainly room for the market to grow.
The Motley Fool January 19, 2005	Meet the Cash Flow Statement It's the least-known but perhaps most important report. The cash flow statement shows how much money a company is really making as it works through operations, makes investments, and borrows money.
JavaWorld October 2001 Frank Sommers	Survival of the fittest Jini services, Part 3 This article explains the default transaction semantics based on the two-phase locking (2PL) protocol, and offers guidelines for its implementation in services based on activatable RMI objects...
Entrepreneur August 2006 Crystal Detamore-Rodman	Exit Visa With export financing options limited, some states are helping U.S. businesses go global. Could your company do with a ticket abroad?
The Motley Fool July 9, 2004 Charly Travers	Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL.
Food Processing May 2009 Steve Lyman	Maintaining Profitability in Trying Times Food and beverage companies must be relentless on cost control and secure financing sources.
The Motley Fool March 5, 2008 Brian Lawler	PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring.
Entrepreneur October 2004 Crystal Detamore-Rodman	An Acquired Taste Before you buy that business you're craving, consider seller financing to sweeten the deal. It not only gives you additional comfort, but also some protections and advantages that you otherwise might not have.
The Motley Fool May 28, 2008 Brian Lawler	Discovery's Costly Debt Delay Discovery Labs announces a new financing agreement, but it's an expensive arrangement.
The Motley Fool March 15, 2005 Charly Travers	PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note.
PHONE+ October 1, 2009 Kelly M. Teal	Does $1B Twitter Valuation Mean New Tech Bubble? Twitter has yet to show any sort of profit and has no monetization path, and yet investors are stampeding to own part of the company.
Finance & Development March 1, 2001 Neil Gregory & Stoyan Tenev	The Financing of Private Enterprise in China A 1999 survey of more than 600 private Chinese enterprises revealed that they relied primarily on self-financing. For China's private sector to thrive, firms will need increased access to external loan and equity financing...
The Motley Fool April 16, 2008 Dave Mock	Wireless Leaders Take an Oath Wireless companies strike an agreement to cap the royalty fees they earn for products using a technology platform called LTE, or "Long Term Evolution."
The Motley Fool May 23, 2007 Dave Mock	Qualcomm Shares the Wealth With the $200 million that Qualcomm intends to spend on legal defense this year, the company is going to great lengths to ensure that it can keep giving back to shareholders.
The Motley Fool March 15, 2005 Lawrence Meyers	Pharma's Outsourcing Elixir Pharmaceutical Product Development saves the drug companies money. Solid financials suggest it's a prescription that's working. Investors who do their due diligence may also find a few dollars earned in their brokerage accounts as well.
The Motley Fool May 11, 2006 Brian Gorman	Albany Molecular Stabilizes The chemistry services company's results are still slumping, but the worst appears to be over. Investors, take note.
The Motley Fool February 6, 2006 Mathew Emmert	Is the Party Over for Canadian Trusts? With new tax changes, navigating the world of Canadian Royalty Trusts has become more challenging. But at their core, these vehicles should maintain their appeal to U.S. investors.